Manning Paul B — SEC insider filings

SEC reporting owner CIK 1494695. 55 insider filings on record with FilingPulse; latest filed 2026-10-02.

Transaction summary — filings shown

Covers the 50 most recent of 55 filings on record, filed 2020-09-30 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Verrica Pharmaceuticals Inc. (VRCA)Director, 10% owner79 legs · 32,799,224 sh · $39,889,554—11
Liquidia Corp (LQDA)Director164 legs · 1,206,977 sh · $7,499,9939 legs · 870,837 sh · $31,739,53411
Taysha Gene Therapies, Inc. (TSHA)10% owner1213 legs · 20,385,804 sh · $25,148,914—8
Candel Therapeutics, Inc. (CADL)Director146 legs · 3,481,458 sh · $23,910,774—17
Acumen Pharmaceuticals, Inc. (ABOS)10% owner11 leg · 312,500 sh · $5,000,000—5

Insider filings — Manning Paul B

FiledFormIssuerReported transactionsSource
2026-10-024Candel Therapeutics, Inc. (CADL)Grant/award (A): 2,189 (derivative) @ $8.68EDGAR
2026-07-014Candel Therapeutics, Inc. (CADL)Grant/award (A): 2,199 (derivative) @ $8.64EDGAR
2026-06-244Candel Therapeutics, Inc. (CADL)Grant/award (A): 32,000 (derivative) @ $0EDGAR
2026-06-184Liquidia Corp (LQDA)Grant/award (A): 5,882 @ $0EDGAR
2026-06-084Liquidia Corp (LQDA)Sale (S): 11,513 @ $63.13 · Sale (S): 88,487 @ $64.28 · Sale (S): 19,125 @ $62.62 · Sale (S): 68,265 @ $63.83 · Sale (S): 12,610 @ $64.42EDGAR
2026-04-024Candel Therapeutics, Inc. (CADL)Grant/award (A): 4,618 (derivative) @ $4.11EDGAR
2026-02-264Candel Therapeutics, Inc. (CADL)Purchase (P): 550,458 @ $5.45EDGAR
2026-02-124Liquidia Corp (LQDA)Other (J): 55,116 @ $42.63 · Other (J): 55,116 @ $42.63EDGAR
2025-11-254Verrica Pharmaceuticals Inc. (VRCA)Purchase (P): 1,375,380 @ $4.24 · Purchase (P): 2,750,762 @ $4.24 · Purchase (P): 343,845 (derivative) · Purchase (P): 687,690 (derivative)EDGAR
2025-09-024Liquidia Corp (LQDA)Sale (S): 154,337 @ $27.94 · Sale (S): 188,232 @ $27.62 · Sale (S): 254,038 @ $28.67 · Sale (S): 74,230 @ $29.14EDGAR
2025-06-264Candel Therapeutics, Inc. (CADL)Grant/award (A): 1,070,663 @ $4.67EDGAR
2025-06-204Liquidia Corp (LQDA)Grant/award (A): 18,396 @ $0EDGAR
2025-06-184Candel Therapeutics, Inc. (CADL)Grant/award (A): 14,240 (derivative) @ $0EDGAR
2025-06-034Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 750,000 @ $2.75EDGAR
2024-12-184Candel Therapeutics, Inc. (CADL)Purchase (P): 500,000 @ $6 · Purchase (P): 750,000 @ $6EDGAR
2024-11-264Verrica Pharmaceuticals Inc. (VRCA)Purchase (P): 18,426,966 · Purchase (P): 4,494,382 · Gift (G): 450,000 @ $0 · Purchase (P): 9,213,483 (derivative) · Purchase (P): 9,213,483 (derivative) · Purchase (P): 2,247,191 (derivative) · +1 moreEDGAR
2024-09-234Verrica Pharmaceuticals Inc. (VRCA)Gift (G): 2,675,611.25 @ $0 · Gift (G): 891,870.41 @ $0 · Gift (G): 891,870.42 @ $0 · Gift (G): 891,870.42 @ $0EDGAR
2024-09-164Liquidia Corp (LQDA)Purchase (P): 337,078 @ $8.90EDGAR
2024-07-014Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 1,333,333 @ $2.25EDGAR
2024-06-274Candel Therapeutics, Inc. (CADL)Grant/award (A): 14,240 (derivative) @ $0EDGAR
2024-06-244Liquidia Corp (LQDA)Grant/award (A): 20,359 @ $0EDGAR
2023-12-184Liquidia Corp (LQDA)Purchase (P): 279,330 @ $7.16EDGAR
2023-11-204Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 100,000 @ $1.63EDGAR
2023-08-164Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 16,466,667 @ $0.90EDGAR
2023-07-244Verrica Pharmaceuticals Inc. (VRCA)Purchase (P): 200,000 @ $5.02EDGAR
2023-06-294Candel Therapeutics, Inc. (CADL)Grant/award (A): 14,240 (derivative) @ $0EDGAR
2023-06-214Liquidia Corp (LQDA)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-11-024Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 1,500,000 @ $2EDGAR
2022-10-174Candel Therapeutics, Inc. (CADL)Grant/award (A): 14,240 (derivative) @ $0EDGAR
2022-07-054Verrica Pharmaceuticals Inc. (VRCA)Purchase (P): 4,761,904 @ $2.10EDGAR
2022-06-224Liquidia Corp (LQDA)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-224Taysha Gene Therapies, Inc. (TSHA)Grant/award (A): 15,500 (derivative) @ $0EDGAR
2022-04-204Liquidia Corp (LQDA)Grant/award (A): 435,674 @ $0EDGAR
2022-04-194Liquidia Corp (LQDA)Purchase (P): 392,156 @ $5.10EDGAR
2022-02-044Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 58,000 @ $7.77 · Purchase (P): 45,000 @ $7.77 · Purchase (P): 22,000 @ $7.77 · Purchase (P): 50,000 @ $7.84 · Purchase (P): 26,602 @ $7.84EDGAR
2021-12-064Verrica Pharmaceuticals Inc. (VRCA)Purchase (P): 30,023 @ $9.45 · Purchase (P): 19,977 @ $9.22EDGAR
2021-11-294Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 2,202 @ $13.19EDGAR
2021-11-244Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 20,000 @ $12.54EDGAR
2021-09-014Liquidia Corp (LQDA)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-08-044/ACandel Therapeutics, Inc. (CADL)Conversion (C): 679,158 · Conversion (C): 553,752 · Purchase (P): 1,625,000 @ $8 · Conversion (C): 1,669,303 (derivative) @ $0 · Conversion (C): 1,361,069 (derivative) @ $0EDGAR
2021-08-024Candel Therapeutics, Inc. (CADL)Conversion (C): 679,158 · Conversion (C): 553,752 · Conversion (C): 1,669,303 (derivative) @ $0 · Conversion (C): 1,361,069 (derivative) @ $0EDGAR
2021-07-294Candel Therapeutics, Inc. (CADL)Purchase (P): 36,000 @ $7.36 · Purchase (P): 20,000 @ $7.30EDGAR
2021-07-084Acumen Pharmaceuticals, Inc. (ABOS)Conversion (C): 2,950,484 · Purchase (P): 312,500 @ $16 · Conversion (C): 657,985 · Conversion (C): 1,634,515 (derivative) @ $0 · Conversion (C): 1,315,969 (derivative) @ $0 · Conversion (C): 657,985 (derivative) @ $0EDGAR
2021-06-214Taysha Gene Therapies, Inc. (TSHA)Grant/award (A): 15,500 (derivative) @ $0EDGAR
2021-05-174Taysha Gene Therapies, Inc. (TSHA)Purchase (P): 12,000 @ $20.98EDGAR
2021-04-154Liquidia Corp (LQDA)Purchase (P): 198,413 @ $2.52EDGAR
2021-03-294Verrica Pharmaceuticals Inc. (VRCA)Purchase (P): 739,830 @ $14.75EDGAR
2021-03-264Liquidia Corp (LQDA)Grant/award (A): 21,385 (derivative) @ $0EDGAR
2020-11-194Liquidia Corp (LQDA)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2020-09-304Taysha Gene Therapies, Inc. (TSHA)Conversion (C): 3,275,205 · Conversion (C): 2,008,158 · Conversion (C): 11,944 · Conversion (C): 3,006,155 (derivative) @ $0 · Conversion (C): 1,843,193 (derivative) @ $0 · Conversion (C): 10,963 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1494695 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs